These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15291805)

  • 21. Molecular genetics and development of mast cells: implications for molecular medicine.
    Födinger M; Mannhalter C
    Mol Med Today; 1997 Mar; 3(3):131-7. PubMed ID: 9095488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells.
    Ohmori K; Kawarai S; Yasuda N; Tanaka A; Matsuda H; Nishimura R; Sasaki N; Tsujimoto H; Masuda K
    Vet Immunol Immunopathol; 2008 Nov; 126(1-2):43-53. PubMed ID: 18687474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia.
    Nagai S; Ichikawa M; Takahashi T; Sato H; Yokota H; Oshima K; Izutsu K; Hangaishi A; Kanda Y; Motokura T; Chiba S; Yatomi Y; Kurokawa M
    Exp Hematol; 2007 Nov; 35(11):1747-52. PubMed ID: 17976525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature.
    Pardanani A; Tefferi A
    Curr Opin Hematol; 2010 Mar; 17(2):125-32. PubMed ID: 20075725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
    Pedersen M; Rönnstrand L; Sun J
    Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the lineage relationship between mast cells and basophils using the c-kit D816V mutation as a biologic signature.
    Kocabas CN; Yavuz AS; Lipsky PE; Metcalfe DD; Akin C
    J Allergy Clin Immunol; 2005 Jun; 115(6):1155-61. PubMed ID: 15940128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Systemic mastocytosis. A review of current diagnostic and therapeutic approaches].
    Pari F; Zamagni MD; Carnevali C; Pagani M; Rabbi C; Cantore M; Cavazzini G; Aitini E; Smerieri F
    Recenti Prog Med; 1999 Mar; 90(3):169-72. PubMed ID: 10228358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone.
    Pullarkat V; Bedell V; Kim Y; Bhatia R; Nakamura R; Forman S; Sun J; Senitzer D; Slovak ML
    Leuk Res; 2007 Feb; 31(2):261-5. PubMed ID: 16876862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
    Gleixner KV; Rebuzzi L; Mayerhofer M; Gruze A; Hadzijusufovic E; Sonneck K; Vales A; Kneidinger M; Samorapoompichit P; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Sillaber C; Willmann M; Valent P
    Exp Hematol; 2007 Oct; 35(10):1510-21. PubMed ID: 17681669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
    Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct clonal origins of systemic mastocytosis and associated B-cell lymphoma.
    Kim Y; Weiss LM; Chen YY; Pullarkat V
    Leuk Res; 2007 Dec; 31(12):1749-54. PubMed ID: 17544505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct signalling pathways for mutated KIT(V560G) and KIT(D816V) in mastocytosis.
    Chan IJ; Kasprowicz S; Tharp MD
    Clin Exp Dermatol; 2013 Jul; 38(5):538-44. PubMed ID: 23777495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel approaches in the treatment of systemic mastocytosis.
    Quintas-Cardama A; Aribi A; Cortes J; Giles FJ; Kantarjian H; Verstovsek S
    Cancer; 2006 Oct; 107(7):1429-39. PubMed ID: 16948123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.
    Akin C
    J Mol Diagn; 2006 Sep; 8(4):412-9. PubMed ID: 16931579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3.
    Tzankov A; Sotlar K; Muhlematter D; Theocharides A; Went P; Jotterand M; Horny HP; Dirnhofer S
    J Clin Pathol; 2008 Aug; 61(8):958-61. PubMed ID: 18663058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia.
    Demehri S; Corbin A; Loriaux M; Druker BJ; Deininger MW
    Exp Hematol; 2006 Mar; 34(3):284-8. PubMed ID: 16543062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Mastocytosis, classification, biological diagnosis and therapy].
    Arock M
    Ann Biol Clin (Paris); 2004; 62(6):657-69. PubMed ID: 15563424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis.
    Hahn HP; Hornick JL
    Am J Surg Pathol; 2007 Nov; 31(11):1669-76. PubMed ID: 18059223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.